253 related articles for article (PubMed ID: 29031505)
21. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
22. A clinically applicable molecular-based classification for endometrial cancers.
Talhouk A; McConechy MK; Leung S; Li-Chang HH; Kwon JS; Melnyk N; Yang W; Senz J; Boyd N; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Br J Cancer; 2015 Jul; 113(2):299-310. PubMed ID: 26172027
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
24. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
25. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
27. [Environmental and genetic risk factors for endometrial carcinoma].
Sénéchal C; Cottereau E; de Pauw A; Elan C; Dagousset I; Fourchotte V; Gauthier-Villars M; Lae M; Stoppa-Lyonnet D; Buecher B
Bull Cancer; 2015 Mar; 102(3):256-69. PubMed ID: 25725922
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of endometrial cancer and therapeutic implications.
Uppendahl L; Mullany SA; Winterhoff B
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
[TBL] [Abstract][Full Text] [Related]
29. [Current prerequisites for a molecular genetic classification of endometrial cancer].
Vtorushin SV; Malykh RD
Arkh Patol; 2017; 79(3):57-62. PubMed ID: 28631718
[TBL] [Abstract][Full Text] [Related]
30. [New features in the 2014 WHO classification of uterine neoplasms].
Lax SF
Pathologe; 2016 Nov; 37(6):500-511. PubMed ID: 27738815
[TBL] [Abstract][Full Text] [Related]
31. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
[TBL] [Abstract][Full Text] [Related]
33. Response: Analysis of adjuvant therapy in early staged endometrioid endometrial cancer-FIGO 2023 classification.
Mutch D; Gaffney D; Matias-Guiu X; Fotopoulou C; Concin N; Berek JS;
Int J Gynaecol Obstet; 2024 Jun; 165(3):1304-1305. PubMed ID: 38512105
[No Abstract] [Full Text] [Related]
34. Endometrial carcinoma in women aged 40 years and younger.
Garg K; Soslow RA
Arch Pathol Lab Med; 2014 Mar; 138(3):335-42. PubMed ID: 24576029
[TBL] [Abstract][Full Text] [Related]
35. LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.
Marshall AD; van Geldermalsen M; Otte NJ; Anderson LA; Lum T; Vellozzi MA; Zhang BK; Thoeng A; Wang Q; Rasko JE; Holst J
Int J Cancer; 2016 Dec; 139(11):2529-39. PubMed ID: 27486861
[TBL] [Abstract][Full Text] [Related]
36. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression.
Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM
Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160
[TBL] [Abstract][Full Text] [Related]
37. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
38. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
[TBL] [Abstract][Full Text] [Related]
39. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Auguste A; Genestie C; De Bruyn M; Adam J; Le Formal A; Drusch F; Pautier P; Crosbie EJ; MacKay H; Kitchener HC; Powell M; Pollock PM; Mileshkin L; Edmondson RJ; Nout R; Nijman HW; Creutzberg CL; Bosse T; Leary A
Mod Pathol; 2018 Dec; 31(12):1851-1861. PubMed ID: 29955143
[TBL] [Abstract][Full Text] [Related]
40. Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumors.
Ritterhouse LL; Howitt BE
Surg Pathol Clin; 2016 Sep; 9(3):405-26. PubMed ID: 27523969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
